August 4, 2026 · Annals of surgical oncology · DOI: 10.1245/s10434-026-20255-6

Secondary Cytoreductive Surgery ± Hyperthermic Intraperitoneal Chemotherapy for Recurrent Colorectal Cancer Peritoneal Metastases

Listen to this summary

The authors aimed to evaluate the safety and oncologic benefit of secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) for patients with recurrent colorectal cancer peritoneal metastases (CRC-PM). Their findings indicate that secondary CRS±HIPEC is safe and associated with improved overall survival compared to initial CRS±HIPEC alone, suggesting it may be a viable option for well-selected patients experiencing recurrence.

Kailey M Oppat, Frances J Bennett, Sameer H Patel, Mustafa Raoof, Joel M Baumgartner, Harveshp D Mogal, Laura A Lambert, Daniel E Abbott, Jonathan B Greer, Travis E Grotz, Keith F Fournier, Sean P Dineen, Benjamin Powers, Mohammad Y Zaidi, Joshua H Winer, Maria C Russell, Charles A Staley, Jordan M Cloyd, Shishir K Maithel, Seth J Concors

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play